Eli Lilly will report its Q3 2026 earnings on October 29, following five consecutive beats on earnings per share (EPS). The company showed strong revenue growth last quarter, driven by blockbuster drugs Mounjaro and Zepbound, with management raising full-year revenue guidance twice. Key catalysts for the upcoming report include potential further guidance raises, volume growth offsetting price declines, and progress on new drugs Foundayo and retatrutide. Despite competition and pricing pressures, these factors could sustain investor optimism and drive a stock rally.
Eli Lilly trades at USD 1,273.46 on Pluang as of Oct 25, 2026 22:51 WIB, down 2.54% in one day. The stock's market cap stands at $1.14 trillion with a dividend yield of 0.54%. Pluang investors show balanced interest, with 52% buying and 48% selling the stock currently.
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
